To further confirm that MUC4 inhibition was a gene transcriptional effect of canertinib treatment, we adopted RT-PCR approach by isolating RNA from pancreatic cancer cells treated with canertinib and its corresponding vehicle control. The gene discussed is MUC4; the disease is pancreatic neoplasm.